COVID-19 and anticoagulant based therapeutics: Approach with great promise
Open Access
- 7 October 2020
- journal article
- letter
- Published by Elsevier BV in Journal of Infection and Public Health
- Vol. 14 (5), 681-682
- https://doi.org/10.1016/j.jiph.2020.09.014
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health systemHospital Practice, 2020
- Coagulation abnormalities and thrombosis in patients with COVID-19The Lancet Haematology, 2020
- Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for actionBritish Journal of Haematology, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19The New England Journal of Medicine, 2020
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-UpJournal of Invasive Cardiology, 2020
- Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathyJournal of Thrombosis and Haemostasis, 2020
- Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic targetIntensive Care Medicine, 2020
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020